232 related articles for article (PubMed ID: 27883291)
1. Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.
Hattinger CM; Vella S; Tavanti E; Fanelli M; Picci P; Serra M
Pharmacogenomics; 2016 Dec; 17(18):2097-2114. PubMed ID: 27883291
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
Hattinger CM; Tavanti E; Fanelli M; Vella S; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):245-257. PubMed ID: 27758143
[TBL] [Abstract][Full Text] [Related]
3. Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
Hattinger CM; Biason P; Iacoboni E; Gagno S; Fanelli M; Tavanti E; Vella S; Ferrari S; Roli A; Roncato R; Giodini L; Scotlandi K; Picci P; Toffoli G; Serra M
Oncotarget; 2016 Sep; 7(38):61970-61987. PubMed ID: 27566557
[TBL] [Abstract][Full Text] [Related]
4. Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?
Kager L; Diakos C; Bielack S
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1025-8. PubMed ID: 25882838
[TBL] [Abstract][Full Text] [Related]
5. Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.
Hattinger CM; Patrizio MP; Luppi S; Magagnoli F; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):299-311. PubMed ID: 30822170
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.
Hattinger CM; Patrizio MP; Luppi S; Serra M
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629971
[TBL] [Abstract][Full Text] [Related]
7. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy.
Bacci G; Briccoli A; Longhi A; Ferrari S; Mercuri M; Faggioli F; Versari M; Picci P
Acta Oncol; 2005; 44(7):748-55. PubMed ID: 16227167
[TBL] [Abstract][Full Text] [Related]
8. Expression profiles of osteosarcoma that can predict response to chemotherapy.
Man TK; Chintagumpala M; Visvanathan J; Shen J; Perlaky L; Hicks J; Johnson M; Davino N; Murray J; Helman L; Meyer W; Triche T; Wong KK; Lau CC
Cancer Res; 2005 Sep; 65(18):8142-50. PubMed ID: 16166288
[TBL] [Abstract][Full Text] [Related]
9. The role of pharmacogenetics in the treatment of osteosarcoma.
Vos HI; Coenen MJ; Guchelaar HJ; Te Loo DM
Drug Discov Today; 2016 Nov; 21(11):1775-1786. PubMed ID: 27352631
[TBL] [Abstract][Full Text] [Related]
10. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.
Hattinger CM; Serra M
Expert Opin Drug Metab Toxicol; 2015; 11(9):1449-63. PubMed ID: 26095223
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing.
Hattinger CM; Casotti C; Patrizio MP; Luppi S; Fantoni L; Scotlandi K; Ibrahim T; Serra M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233089
[TBL] [Abstract][Full Text] [Related]
12. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.
Windsor RE; Strauss SJ; Kallis C; Wood NE; Whelan JS
Cancer; 2012 Apr; 118(7):1856-67. PubMed ID: 21887680
[TBL] [Abstract][Full Text] [Related]
13. An update on emerging drugs in osteosarcoma: towards tailored therapies?
Hattinger CM; Patrizio MP; Magagnoli F; Luppi S; Serra M
Expert Opin Emerg Drugs; 2019 Sep; 24(3):153-171. PubMed ID: 31401903
[No Abstract] [Full Text] [Related]
14. Current treatment of high grade osteosarcoma of the extremity: review.
Bacci G; Lari S
J Chemother; 2001 Jun; 13(3):235-43. PubMed ID: 11450880
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study.
Fagioli F; Aglietta M; Tienghi A; Ferrari S; Brach del Prever A; Vassallo E; Palmero A; Biasin E; Bacci G; Picci P; Madon E
J Clin Oncol; 2002 Apr; 20(8):2150-6. PubMed ID: 11956277
[TBL] [Abstract][Full Text] [Related]
16. An update on chemotherapy for osteosarcoma.
Ferrari S; Serra M
Expert Opin Pharmacother; 2015; 16(18):2727-36. PubMed ID: 26512909
[TBL] [Abstract][Full Text] [Related]
17. The pharmacogenomics of osteosarcoma.
Serra M; Hattinger CM
Pharmacogenomics J; 2017 Jan; 17(1):11-20. PubMed ID: 27241064
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma.
Akazawa R; Umeda K; Saida S; Kato I; Hiramatsu H; Sakamoto A; Arakawa Y; Sumiyoshi S; Okamoto T; Moritake H; Adachi S; Takita J
Jpn J Clin Oncol; 2020 Aug; 50(8):948-952. PubMed ID: 32463097
[TBL] [Abstract][Full Text] [Related]
19. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience.
Chi SN; Conklin LS; Qin J; Meyers PA; Huvos AG; Healey JH; Gorlick R
Pediatr Blood Cancer; 2004 Jan; 42(1):46-51. PubMed ID: 14752794
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients.
Berger M; Grignani G; Ferrari S; Biasin E; Brach del Prever A; Aliberti S; Saglio F; Aglietta M; Fagioli F
Cancer; 2009 Jul; 115(13):2980-7. PubMed ID: 19452540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
